Land: Írland
Tungumál: enska
Heimild: HPRA (Health Products Regulatory Authority)
DACARBAZINE CITRATE
Medac Gesellschaft fur Klinische Spezialpraparate
DACARBAZINE CITRATE
100 Milligram
Pdr for Soln Inj/Inf
Product subject to prescription which may not be renewed (A)
Withdrawn
2013-11-13
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dacarbazine medac 100 mg, Powder for solution for injection or infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each single-dose vial of Dacarbazine medac 100 mg contains 100 mg dacarbazine (as dacarbazine citrate, formed _in_ _situ_). After reconstitution Dacarbazine medac 100 mg contains 10 mg/ml dacarbazine (see section 6.6). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Dacarbazine medac 100 mg: Powder for solution for injection or infusion. Dacarbazine medac is a white or pale yellow powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dacarbazine is indicated for the treatment of patients with metastasized malignant melanoma. Further indications for dacarbazine as part of a combination chemotherapy are: o Advanced Hodgkin’s disease. o Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The use of dacarbazine should be confined to physicians experienced in oncology or haematology respectively. Dacarbazine is sensitive to light exposure. All reconstituted solutions should be suitably protected from light also during administration (light-resistant infusion set). Care should be taken of administration of the injection to avoid extravasation into tissues since this will cause local pain and tissue damage. If extravasation occurs, the injection should be discontinued immediately and any remaining portion of the dose should be introduced into another vein. The following regimes can be used. For further details cf. current scientific literature. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 25/05/2012_ _CRN 2108036_ _page number: 1_ MALIGN Lestu allt skjalið